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Purinergic signalling plays a crucial role in immunity and autoimmunity. Among puri-
nergic receptors, the P2X7 receptor (P2X7R) has an undisputed role as it is expressed to high
level by immune cells, triggers cytokine release and modulates immune cell differentia-
tion. In this review, we focus on evidence supporting a possible role of the P2X7R in the
pathogenesis of systemic lupus erythematosus (SLE).Rat mast cells were the first inflammatory cells in which the
effects of extracellular ATP where described, but with little
insight into the possible pathophysiological meaning [1,2].
Later experiments suggested that the potent Ca2þ-dependent
histamine-releaseactivity due to extracellularATP involvedan
unusual increase in cation permeability of the plasma mem-
brane [3], but it was not until the key experiments byGomperts
that it was formally shown that, difficult to believe as it was,
extracellular ATP caused the opening of a non-selectiverphology, Surgery and E
3; fax: þ39 0532 455351.
).
g Gung University.
ublishing services by Else
/by-nc-nd/4.0/).plasma membrane pore [4]. Over thirty-six years later, we
can now appreciate in full the profound implications of this
ATP-dependent response in virtually all pathophysiological
processes, immunity in the first place. Plasma membrane re-
ceptors for extracellular ATP, intracellular transduction
mechanisms, coupling factors and even crystal structure (for
someP2 receptors) havebeen resolved. The challenge is now to
take all this knowledge to the patient's bed. This reviewaims to
fill, at least in part, the gap to the clinics.xperimental Medicine, University of Ferrara, Via Savonarola, 9,
vier B.V. This is an open access article under the CC BY-NC-ND
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Adenosine triphosphate (ATP) has been for long time consid-
ered only involved in cell metabolism as the main source of
energy, any possible role in extracellular signalling being
virtually unthinkable. Thus, the proposal of the purinergic
hypothesis for neurotransmission put forward by Geoffrey
Burnstock in the 1970's after having identified ATP as a
transmitter between non-adrenergic neurons and muscle [5]
was received with surprise and even with outright scepti-
cism. Scientific community was somewhat schizophrenic
about the “purinergic hypothesis” since on the one hand
pharmacologists and physiologists accumulated countless
data supporting the presence and functional relevance of cell
receptors for extracellular ATP, while on the other bio-
chemists, cell biologists and immunologists simply ignored
the whole of these experimental observations, and when
some attention was paid to the theme, they were often
referred to as artifacts. With the molecular cloning of the first
P2 receptor (P2R), P2Y1 (P2Y1R) [6], ATP-receptors gained a
novel dignity in the realm of cell receptors and started to
attract the attention of scientists from outside the pharma-
cology and physiology communities. Nowadays, “purinergic
signalling” is a well-established concept in biomedical science
and represents an important and expanding subject of
research in many different areas, including immunology,
oncology, developmental biology, physiology, neurobiology,
not to say of pharmacology and medicinal chemistry [7,8].
Although the first evidence of a role for purinergic receptors
was in neurotransmission, it became clear soon that extra-
cellular ATP and adenosine play a crucial role in basically all
processes requiring cell-to-cell communication. It is now
thought that release of ATP and other purine or pyrimidine
nucleotides represents a widespread mean of cell-to-cell
communication highly conserved throughout evolution, as
suggested by the discovery of ATP-receptors in invertebrates
[9], slimemoulds [10], fishes [11], and obviouslymammals [12].
It was initially thought (and many investigators still hold
this view) that ATP is mainly if not exclusively released as a
consequence of cell death or plasma membrane injury. This
view has radically changed over the latest few years with the
discovery that virtually all cells are capable of non-lytic ATP
release. Several pathways have been identified: secretory
vesicles [13,14], ABC transporters [15], pannexins [16], con-
nexins [17] and possibly the P2X7 receptor (P2X7R) [18,19].
Once in the extracellular milieu, ATP is converted to
adenosine through the enzymatic activity of two membrane-
bound nucleotidases, CD39 and CD73. Adenosine extracel-
lular concentration is generally constant in most tissues but
can rapidly undergo a 100-fold increase in hypoxic or inflamed
sites exerting multiple immunosuppressive effects virtually
on all immune cell types.
Purinergic receptors are classified into P1 (P1Rs) and P2
(P2Rs) receptors. P1Rs, adenosine selective, are comprised of
four subtypes, A1, A2A, A2B, and A3. P2Rs, nucleotide selec-
tive, include two sub-families characterized by distinct phar-
macological profiles: metabotropic P2YRs and ionotropic
P2XRs. P2YRs are subdivided into eight subtypes: five Gq/G11-
coupled subtypes, associated to phospholipase C (PLC)activation and inositol triphosphate (IP3) generation (P2Y1R,
P2Y2R, P2Y4R, P2Y6R and P2Y11R), and three Gi/o-coupled
subtypes associated to adenylate cyclase inhibition and
modulation of ion channels (P2Y12R, P2Y13R and P2Y14R) [20].
P2Y11R also couples to Gs to promote adenylate cyclase
stimulation, thus its activation causes an intracellular Ca2þ
rise as well as an increase in cAMP levels. P2YRs are activated
by low (nanomolar) nucleotide concentrations, and since
signal transduction requires generation of soluble intracel-
lular second-messengers, cellular responses triggered by
these receptors are rather slow. Different nucleotides are
active at P2YRs, P2Y11R being the only P2YR at which ATP is
the preferred agonist. The other P2YRs recognize as preferred
ligands ADP (P2Y12R and P2Y13R), UTP (P2Y4R), UDP (P2Y6R),
UDP-glucose or UDP-galactose (P2Y14R), and with equal po-
tency ATP and ADP (P2Y1R) or ATP and UTP (P2Y2R) [21].
P2XRs are trimeric ion channels permeable to monovalent
(Naþ, Kþ) and divalent (Ca2þ) cations. ATP is the only known
physiologic agonist. Functional P2XR channels may be formed
by the assembly of the same P2X subunit (homomeric chan-
nels), or different P2X subunits (heteromeric channels) [22].
Six homomeric (P2X1R-P2X5R and P2X7R) and six heteromeric
(P2X1/2R, P2X1/4R, P2X1/5R, P2X2/3R, P2X2/6R and P2X4/6R)
receptors have been described so far [23]. Among P2X sub-
units, P2X7 is generally thought not to assemble with the
others, and thus form only P2X7 homomeric channels. An
early report evidence suggested that P2X7 subunits may also
associate with other subunits (P2X4) to form heteromeric
channels [24], but later experiments were unable to confirm
these findings [25], thus enforcing the view that P2X7Rs “stand
alone” in the plasma membrane.
P2X subunits length ranges from 379 (P2X6) to 595 (P2X7)
amino acids. Each subunit consists of two membrane span-
ning segments (TM1 and TM2) separated by an extracellular
loop containing ten conserved cysteine residues [26], thought
to form disulfide bonds, and lysine and phenylalanine resi-
dues involved in activation by ATP [27]. Both C and N termini
are intracellular. The carboxyl-terminal tail of the various P2X
subunits varies in length from 25 amino acids (P2X6) to 240
amino acids (P2X7) and plays a key role in setting the distinct
functional features of each receptor [28,29]. Electrophysiology
data show that P2X channel activation requires binding of
three ATP molecules to the extracellular domain [30]. Sensi-
tivity of ATP-binding widely varies within the family, ranging
from low nM levels required for P2X1R activation, to high mM
or even mM concentrations necessary to switch on the P2X7R
[31]. Cations and anions in extracellular medium also modu-
late P2XR activity [28,32].
Brief exposure of all P2XRs to ATP causes a fast (millisec-
onds) opening of a channel that renders the plasmamembrane
permeable to positively charged ions, causing increase in
intracellular Ca2þ and Naþ and a simultaneous decrease in
intracellular Kþ concentrations. Significant Ca2þ permeability
of P2X receptors implies a selective filter involving TM1 and
TM2 [33,34]. Channel opening leads to cell membrane depo-
larisation and initiation of downstream Ca2þ signalling events
[31]. On the contrary, prolonged exposure to ATP has different
effects depending on the receptor sub-type: P2X1R and P2X3R
undergo fast desensitisation and channel closing, whereas
P2X2R, P2XR4, P2X5R and the P2X7R are slowly desensitizing.
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cally unable to form a functional channel. It was originally
shown that sustained activation of the P2X7R caused opening
of a large transmembrane pore permeable to hydrophilic mol-
ecules of MW up to 900 Da [28,35e40]. Later experiments sug-
gested that other P2XR subtypes such as P2X2R and P2X4Rwere
also endowed with the ability to generate a large plasma
membrane pore upon sustained activation [41,42]. However, it
is now an established fact that, although in some instances also
P2X2R or P2X4Rmay undergo a channel-to-pore transition, this
process is far easier to observe and is much more easily
reproduced and analysed in cell expressing the P2X7R. In most
P2X7R-expressing cells extracellular ATP promotes a true pro-
cess of reversible plasma membrane permeabilization that,
upon ATP removal and plasma membrane resealing, leaves
intact most cellular physiological responses [37]. Recent elec-
trophysiology data cast doubts on the P2X2R-dependent in-
creases in plasma membrane permeability previously
documented [43]. Therefore, it is fair to say that the channel-to-
pore transition leading to ATP-stimulated reversible plasma
membrane permeabilization is indeed a signature of the P2X7R.
Strong evidence supports of a key role of P2Rs in multiple
different physiological and pathophysiological responses
such as neuromuscular transmission [44], neuron-to-neuron
communication [45], bladder function [46], inflammation
[47], arthritis [48], neurodegeneration [49], cancer [50], chronic
and inflammatory pain [51e53], bone formation and resorp-
tion [54], male fertility [44,55] blood pressure regulation [56],
blood coagulation and thrombosis [57]. Moreover, P2Rs are up-
regulated following tissue damage, as for example in periph-
eral nerve injury [58], spinal cord injury [59], brain ischaemia
[60], and more in general in inflammation and in cancer
[61,62]. Thus, P2Rs are involved in a wide spectrum of dis-
eases, a finding not surprising in view of the ubiquitous dis-
tribution of these receptors.
There is no doubt that the P2R for which disease relevance
is more compelling is P2Y12R. Its high level of expression in
platelets and the crucial role in blood coagulation has led to
the development of very effective anti-thrombotic drugs that
for years have been block-busters in the world drug market
[63]. Among P2XRs, the most likely candidate target for suc-
cessful drug development is the P2X7R. This receptor is
thought to have an important immunomodulatory function
not just because of its well-known ability to activate the
NLRP3 inflammasome (and therefore IL-1b release), but also
for its crucial role in T lymphocyte growth and differentiation.
Participation of the P2X7R in many chronic inflammatory
diseases, ranging from arthritis [64] to gout [65], from tuber-
culosis [66] to chlamydia infection [67] has been postulated. In
this reviewwewill explore themain features and functions of
the P2X7R receptor together with its possible role in systemic
lupus erythematosus (SLE), one of the human pathologies
more strongly characterized by immune-mediated tissue
damage and inflammation.The P2X7R receptor
The P2X7R is widely distributed in human tissues with the
highest expression in cells of the immune and inflammatorysystems, especially of the monocyte-macrophage lineage [68].
The P2X7R gene is located on human chromosome 12q24
(locus 12q24.31), close to the P2X4R locus (12q24.32). Both full
length P2X7R (P2X7RA) and the carboxyl-terminal truncated
splice variant P2X7RB show high sequence homology with the
P2X4R (41% identity, 71% similarity), a finding suggestive of a
common origin. Therefore, information about P2X7R structure
and ligand binding might be deducted from the crystal
structure solved for the homologous zebrafish P2X4R [69,70].
The P2X7R is an oligomer made of three subunits [22]
which binds three ATP molecules at sites at the interface be-
tween subunits. Activation of the receptor by ATP triggers a
sigmoid dose response curve with a Hill coefficient value be-
tween of 2.0 and 2.4, suggesting an allosteric effect facilitating
sequential binding of the three ATP molecules [71,72]. Hill
coefficient is about 3 with benzoyl ATP as an agonist [72]. By
analogy with the P2X4R data, it can be inferred that ATP binds
at an inter-subunit binding pocket lined with several posi-
tively charged residues (R298, K316, N296, K70, K193, T189,
K72) located on a protein fold not found in other conventional
ATP-binding sites [70].
The P2X7R is the P2XR in which the ion channel-to-large
pore transition has been more thoroughly described and in
which is best reproducible [36e38]. Stimulation with low ATP
concentrations triggers opening of the typical cation-selective
channel, whereas challenge with higher agonist concentra-
tions (mM-mM) causes formation of the large non-selective
pore [29,36,73]. The molecular mechanism of channel-to-
pore transition has long been a matter of controversy. Most
credited hypotheses hold that the large conductance pore
results from either 1) dilation of the cation channel, or 2)
recruitment of an accessory molecule, e.g. pannexin-1 [74,75].
Data from pannexin-1 KO mice however indicate that
pannexin-1 is not an absolute requirement for large conduc-
tance pore formation (Cavagna and Di Virgilio, unpublished),
thus suggesting that either recruitment of another plasma
membrane molecule occurs, or that it is the cation channel
itself that dilates to generate the non-selective pore. In fact,
pore shaping was supposed to depend on agonist-induced
movements of TM1 and TM2 helices, hence implying dilata-
tion of the intrinsic channel. The stoichiometry of the P2X7R
channel/pore might in principle help to discriminate between
these two mechanistic alternatives. Current consensus holds
that the P2X7R channel is made by the assembly of three
identical subunits (homotrimer), however anecdotal evidence
from past studies raises the possibility that higher assembly
states might also be present. Surprenant's group initially
showed that in BN-PAGE specific anti-P2X7R Abs stain a
400 kDa band both in HEK293 cells transfected with the rat
P2X7R and in rat peritoneal macrophages, suggesting that
both heterologously expressed and native rat P2X7R, may
include 5e6 subunits [76]. As a warning of caution, these au-
thors admit that the 400 kDa band both might include some
yet-to-identify interacting proteins. Several years ago, we
determined receptor stoichiometry in the absence and pres-
ence of the antibiotic polymixin B in humanmacrophages and
in HEK293 cells stably expressing the human P2X7R [77]. Pol-
ymixin B potentiates P2X7R responses because it likely acts as
a positive allosteric modulator [78]. P2X7R analysis on dena-
turing gel revealed a 440 kDa band that was strongly enhanced
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prenant's and our laboratory suggest that while a trimeric
stoichiometry is the prevalent state of assembly, it cannot be
excluded that higher molecular weight states also occur.
Summarizing, two distinct pathways are thought to be
implicated in agonist-stimulated pore formation, the first
directly depending on conformational changes intrinsic to
P2X7R [12,75], whereas the second presumably involving
P2X7R-dependent recruitment of plasma membrane hemi-
channels [74,79].
A number of polymorphisms and splicing variants confer
an intriguing plasticity to P2X7R [80e82]. P2X7R poly-
morphisms include both gain- and loss-of-function variants,
some of them presumably involved in different pathologies,
such as cancer [83,84], osteoporosis [85e87] and increased
susceptibility to tuberculosis [88,89]. Alternative splicing is
responsible for 23 P2X7R mRNA transcripts listed in NCBI
database. Eighteen of them are predicted to produce P2X7R
protein variants, including the full length P2X7RA, and the
human P2X7RB isoform that lacks the cytoplasmic carboxyl
tail (GenBank accession No. AY847298.1) [81]. Heterologous
expression in HEK293 cells showed that the P2X7RB isoform
generates a cation-selective channel, but not the large
conductance pore [90]. P2X7RB has also been shown to form
heterotrimers with P2X7RA resulting in stabilization of the
receptor and potentiation of the associated responses,
including channel and pore formation [91,92].
P2X7R is involved in many different cell functions. This is
witnessed by proteomic studies showing a link of P2X7R with
different intracellular proteins, among which cytoskeletal (b-
actin) and signalling proteins (protein tyrosine phosphatase,
phosphatidylinositol kinases) as well as chaperones (HSP70
and HSP90). Association of P2X7R with different intracellular
partners might thus be responsible for cell type-specific re-
sponses. In addition to the plasmamembrane, P2X7R has also
been localized to intracellular membranes, i.e. endoplasmic
reticulum and nuclear membrane [93,94].
Participation of P2X7R in several relevant pathophysiolog-
ical processes has been demonstrated. First of all, P2X7R is a
key trigger for maturation and release of the pro-
inflammatory cytokines interleukin-1b (IL-1b) and inter-
leukin 18 (IL-18) via activation of the NOD-like receptor (NLR)
P3 inflammasome, the cytoplasmic organelle responsible for
the conversion of pro-caspase-1 into active caspase-1 [95e98].
While the mechanism of NLRP3 inflammasome activation by
P2X7R is as yet incompletely understood, a key role is thought
to be played by Kþ efflux (see Di Virgilio et al. [99] and Munoz-
Planillo et al. [100]). Other evidence suggests that the NLRP3
inflammasome can also be activated by reactive oxygen spe-
cies, which incidentally are also produced following P2X7R
stimulation [101,102]. In addition, direct P2X7R interaction
with NLRP3 cannot be excluded [103]. The intracellular Kþ
drop triggers a cascade of events leading to NLRP3 activation
and pro-caspase-1 cleavage. The P2X7R also plays amajor role
in the mechanism of secretion of IL-1b. As it is well known,
this cytokine lacks a leader sequence necessary for its tar-
geting to the conventional cellular secretion pathway, thus
alternative release pathways have been investigated. Such
unconventional pathways include exosome (30e80 nm), and/
or microvesicle (100 nme1 mm) release [104].Several signalling pathways are activated following P2X7R
stimulation such as changes in intracellular Ca2þ and activa-
tion of transcription factors including nuclear factor kappa B
(NF-kB) [105e107], hypoxia inducible factor 1a (HIF-1a) [108]
and the nuclear factor of activated T cells complex 1
(NFATc1) [90,109]. NFATc1, a key transcription factor in
normal and neoplastic cell growth, plays a central role in
P2X7R-mediated proliferation, as demonstrated on one hand
by its strong up-regulation in HEK293 cells expressing the A
and B P2X7R isoforms [91,92], and on the other by abrogation
of P2X7R-dependent cell growth following its blockade by se-
lective inhibitors, such as cyclosporine or VIVIT [90]. Addi-
tional intracellular signalling pathways are also P2X7R-
associated, such as the MAP-kinase [110] and the PI3K/Akt
pathways [111]. Finally, P2X7R has a central role also in
carcinogenesis. In fact, its expression supports tumour
growth, both in allogenic (nude/nude host) and syngeneic
mice models [112], as well as tumour associated angiogenesis
[112]. P2X7R expression enhances invasiveness and metasta-
tization, as shown in vitro, by matrigel-infiltration experi-
ments [91], and in vivo, in a zebrafish model of metastasis
[113,114]. Several tumours overexpress P2X7R, e.g. chronic
lymphocytic leukaemia, melanoma, neuroblastoma, prostate,
breast, skin, thyroid cancers and osteosarcoma [92,115]. Quite
interestingly, host-P2X7R as opposed to tumour-P2X7R, is on
the contrary essential to restrict tumour growth, as trans-
planted syngeneic tumours undergo accelerated growth and
metastatic dissemination in the P2X7R-KO host [116].
The P2X7R participates in defense against pathogens since
P2X7R-mediated phospholipase D (PLD) activation facilitates
phagosome-lysosome fusion and therefore intraphagosomal
killing of different microorganisms such as Mycobacterium
tuberculosis and chlamydia [67,117]. An as yet poorly under-
stood P2X7R-dependent process is membrane blebbing fol-
lowed by microvesicle shedding [118e120]. Increasing
evidence suggest that this might be a novel avenue for
dissemination of biologically active factors (e.g. IL-1b or NLRP3
inflammasome components) [121]. In support to an important
role played by P2X7R in chronic inflammation, we showed
that this receptor is involved in multinucleated giant cell
(MGC) formation, whether in a model of heterologous P2X7R
expression [122] or in a more physiological model of sponta-
neous or GM-CSF-stimulated fusion of human or mouse
macrophages [123]. This function was shown to be strictly
dependent on pore-forming activity, since cells transfected
with a P2X7R receptor lacking the C-terminal domain, which
were devoid of pore-forming activity, formed lower number of
MGC respect to cells transfected with the full length P2X7R
receptor [123]. Moreover, P2X7R-dependent ATP release and
its metabolism to adenosine have also been shown to be
necessary for MGC formation and osteoclast fusion [124,125].
The P2X7R is a receptor endowed with a dual role: on one
hand pharmacological stimulation by high ATP doses triggers
cell death, whether by necrosis, apoptosis or pyroptosis, while
on the other hand, tonic, low level of stimulation by endoge-
nously released ATP has a trophic effect [109,126e128]. The
key intracellular target sustaining cytotoxic as well as trophic
P2X7R effects is the mitochondria, as P2X7R overstimulation
triggers a “mitochondrial catastrophe” witnessed by mito-
chondrial swelling, fragmentation and uncoupling of
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stabilizes the mitochondrial network, increases mitochon-
drial potential and enhances the efficiency of oxidative
phosphorylation [109].
Based on the whole of this evidence, P2X7R has become a
promising target for treatment of inflammation and pain
[129,130].P2X7R in the pathogenesis of systemic lupus
erythematosus (SLE)
The P2X7R and related molecules have been implicated in the
pathogenesis of several autoimmune diseases, systemic lupus
erythematosus (SLE) included [131].
SLE is a systemic autoimmune syndrome characterized by
increased type I interferon (IFN) signature, and dysregulation
of both innate and adaptive immune responses [132]. All SLE
patients typically produce autoantibodies to components of
the cell nucleus (anti-nuclear antibodies or ANA), especially
against nucleosomal constituents. Autoantibody binding to
self-antigens leads to formation of a large quantity of immune
complexes whose clearance is inmany cases reduced because
of defects in the complement cascade [133,134]. Immune-
complex deposition within several tissues (e.g. skin, kidney,
brain, bone marrow and lungs) is responsible of the immune-
mediated organ damage characteristic of SLE. In addition,
immune complexes can bind to receptors for advanced gly-
cation end products (RAGE) on endothelial cells, thus causing
immune-mediated vasculitis [135]. Severe clinical manifesta-
tions, included cardiovascular events due to accelerated
atherosclerosis, are frequent in SLE, with an overall increase
in mortality. Release of normally segregated nuclear compo-
nents in SLE has been traditionally put down to defects in the
apoptotic pathway, in particular to the frequent occurrence of
secondary necrosis, a late post-apoptotic phase characterized
by membrane break-down and release of intracellular con-
tent. In alternative to apoptosis, i.e. programmed cell death,
and necrosis, i.e. accidental cell death, two more recently
discovered cell death types, pyroptosis and NETosis, can also
be responsible of release of nuclear content, and thus play a
role in SLE. Pyroptosis, defined as a regulated death specific of
macrophages and dendritic cells [136], is thought to accelerate
immune response against pathogens and to facilitate their
clearance. Pyroptosis requires inflammasome recruitment
and caspase-1 activation, and combines the release of nuclear
elements, such as DNA and HMGB1 (e.g. high mobility group
box 1) protein, and cytoplasmic components (e.g. ATP) with
that of pro-inflammatory cytokines (e.g. IL-1b). On the other
hand, NETosis occurs primarily in neutrophils as another
form of controlled cell death, leading to release of NETs
(neutrophil extracellular trap-associated proteins). NETs are
meshworks of chromatin, anti-microbial peptides and en-
zymes that play an important role in host defense [137,138].
Since DNA, histones and HMGB1 are involved in the patho-
genesis of SLE [139], pyroptosis is suggested to be a main
mechanism responsible for release of HGMB1 in SLE, and
accordingly HMGB1 a possible biomarker of the disease [140].
Different mouse models mimicking human SLE are avail-
able [141]: a) the NZB/W F1 strain, in which especially femalesare affected by a lupus-like disease [142]; b) the MLR/lpr strain,
characterized by the lpr mutation that is known to impair
transcription of the Fas receptor [143]; c) the BXSB/Yaa strain,
in which Yaa is an element termed Y-linked autoimmune
accelerator due to a translocation resulting in duplication of at
least 16 genes, among which TLR7 [144]. Induced models are
also available that provide insight mainly into the role of
environmental factors in SLE pathogenesis. The most
commonly used is the pristane-induced lupus model, ob-
tained by intraperitoneal injections of pristane, an isoprenol
alkane present in mineral oil, that triggers autoantibody for-
mation and glomerulonephritis at level comparable to that
found in MLR/lpr mice [145].
Several observations link SLE to P2X7R. In the first place,
P2X7R inhibition, by either the semi-selective antagonist BBG
or small interfering RNA (siRNA) was shown to reduce
nephritis in MLR/lpr mice models [146]. A substantial up-
regulation of molecules involved in P2X7R-NLRP3 inflamma-
some signalling, namely P2X7R, NLRP3 and ASC, was found in
the kidneys of MLR/lpr mice compared to control mice. BBG
treatment reduced NLRP3/caspase-1 assembly and IL-1b
release, and significantly diminished both the severity of
nephritis and levels of circulating anti-dsDNA antibodies. BBG
also reduced serum levels of both IL-1b and IL-17, and
decreased the Th17:Treg ratio. Genetic deletion of P2X7R
(P2X7R-KO mice) conferred significant protection against
antibody-mediated glomerulonephritis [147]. Moreover, T
lymphocytes from MRL/lpr mice become with age more
resistant to ATP-induced apoptosis [148], possibly because of
P2X7R down-regulation. In humans, increased glomerular and
tubular expression of P2X7R was detected in renal biopsies
from patients with autoimmune-related glomerulonephritis
[149].
Caspase-1 has also been suggested to be involved in SLE
pathogenesis in a model of pristane-induced lupus nephritis.
Caspase-1/ mice show reduced autoantibodies, decreased
type I IFN signature, lower renal inflammation (correlated to
IL-18 levels) and fewer cardiovascular lesions compared to
caspase-1þ/þ mice [150]. In the pathogenesis of pristane-
dependent lupus, caspase-1 might be needed to preserve
anti-DNA-producing Ab B cells in the marginal zone of the
spleen via an IL-18-dependent mechanism [151].
The main product of P2X7R and inflammasome activation,
i.e. IL-1b, is thought to have a major role in SLE pathogenesis.
Significant increase of IL-1b levels in sera from SLE patients
and a correlationwith disease activity has been reported [152].
Moreover, IL-1b/ mice are resistant to development of SLE
triggered by injection of anti-DNAAbs, while IL-1a/mice are
not [153]. IL-1b, together with IL-6 and IL-23, drives the dif-
ferentiation of T helper 17 (Th17) cells [154] that produce IL-17
and have a relevant role in organ specific autoimmunity. IL-
17-producing T cells are increased in peripheral blood from
SLE patients, this cytokine being involved in tissue injury
characteristic of glomerulonephritis [155]. Anothermember of
the IL-1 family, IL-33, has been recently implicated in SLE.
MLR/lpr mice treated with anti-IL-33 Abs showed a reduction
in all hallmarks and symptoms of the disease. Following anti-
IL-33 treatment Tregs and MDSCs were increased whereas
Th17 cells as well as IL-1b, IL-6 and IL-17, were significantly
reduced. A correlation between the expansion of Tregs and
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suggested [156].
IL-18 dysregulation was also observed in SLE. Firstly,
elevated IL-18 serum levels were found in SLE patients. IL-18
serum levels correlated with disease activity, auto Ab pro-
files and the presence of nephritis [157e159]. In addition, the
IL-18 inhibitor, IL-18BP, was also found increased in sera from
SLE patients. Despite higher IL-18P levels, free IL-18 was still
significantly higher than in controls and its serum level was
considered a possible marker of disease activity [160].
Increased IL-18 expression was present in biopsies from
cutaneous lupus lesions. Elevated IL-18 levels might be a
trigger for increased TNF-a expression typical of lupus sub-
acute cutaneous lesions. TNF-a is known to increase kerati-
nocyte sensitivity to apoptosis, with the result of increasing
exposure of modified self-antigens [161]. Interleukin-18 might
also cause dysfunction of endothelial progenitor cells, thus
hindering vascular repair [162]. Finally, IL-18 is reported to
significantly enhance production of NETs, a crucial factor in
inflammasome activation via P2X7R [163].
P2X7R also acts as a receptor for the LL-37 cathelicidin
[164]. LL-37 is a cationic peptide synthesized by neutrophils,
monocytes, keratinocytes and macrophages, active against a
wide range of pathogens. LL-37 appears to play a relevant role
in innate immunity as it promotes chemotaxis [165], M1
macrophage differentiation [166] and enhanced TLR3 signal-
ling in response to viral dsRNA [167]. LL-37 can form com-
plexes with dsDNA thus stimulating a large type I IFN release
by plasmacytoid dendritic cells (pDCs) [168]. LL-37 is a
component of NETs, on which it can be externalized. NETs,
that are a combination of chromatin and defense-related
proteins, are increased in patients with SLE and likely
contribute to its pathogenesis [168,169]. P2X7R activation
represents a fundamental step in LL-37-mediated release of
IL-1b from peripheral bloodmonocytes [164,170]. NETs and LL-
37-mediated activation of the inflammasome via P2X7R is
increased in macrophages from lupus patients [163]. It has
been proposed that a feature of SLE is an imbalance between
NETs formation and clearance, thus leading to endothelium
damage, exposure of immune-stimulatory molecules and
tolerance break-down [137,169,171]. Indeed a distinct sub-set
of pro-inflammatory low-density granulocytes (LDGs)
showed enhanced capacity to form NETs in lupus patients
[169,172]. Thus, enhanced NET release in lupus patients may
lead to increased P2X7R and NLRP3 inflammasome activation
and enhanced release of IL-1b and IL-18. The result is an auto-
stimulatory loop leading to further stimulation of NETosis and
amplification of the inflammatory response potentially
responsible for disease flares and organ damage [163]. Dysre-
gulated expression and/or activity of P2X7R in lupus patients
might further fuel this pro-inflammatory mechanism.
The P2X7R ligand, ATP, can be released from the cells in
different conditions ranging from necrotic cell death to active
extrusion via specific transport systems, among which P2X7R
itself. Of relevance in LES, complement, especially the C3a
component, is a stimulus for ATP release, thus acting as
inflammasome activator [173]. Extracellular ATP via P2X7R
induces release of another alarm molecule, i.e. HMGB1
[121,174,175,176]. HMGB1 is a highly conserved non-histone
nuclear protein whose function is to bind structural nuclearelements. In analogy to ATP, HMGB1 is both passively, i.e.
following cell death, and actively released. All the three pro-
grammed cell death types, i.e. apoptosis, pyroptosis and
NETosis, are accompanied by HMGB1 release. Once in the
extracellular environment HMGB1 acts as a DAMP signal
regulating, in a very complicated way, a wealth of immune
responses. Indeed, depending on the redox state of three
cysteine residues, it can induce immune tolerance, chemo-
taxis or inflammation [177,178]. HMGB1 is released from
apoptotic cells in a redox form that induces immune toler-
ance. On the contrary, the HMGB1 redox form secreted from
cells stimulated via TLRs or undergoing pyroptosis, has pro-
inflammatory activity since it activates NF-kB via TLR4 bind-
ing [179]. HMGB1, besides being released by pyroptotic cells,
can also inducemacrophage pyroptosis by causing cathepsin-
B activation, lysosome disrupture, and consequent caspase-1
activation [180]. Extracellularly, HMGB1 forms complexes
with different molecules, such as self-DNA, LPS and IL-1b,
thus increasing their immunogenicity and eventually leading
to generation of autoantibodies and immunecomplexes
typical of lupus. HMGB1 can be also a component of NETs
[181]. Therefore, P2X7R activation by ATP or by extracellular
complexes, such as NETs, might have a dual pathogenetic role
in promoting inflammation in lupus: on one hand, it directly
triggers inflammation by stimulating the NLRP3 inflamma-
some, and on the other it has an indirect pro-inflammatory
effect by inducing pyroptotic cell death. In genetically pre-
disposed subjects, pyroptosis can contribute to autoimmune
responses by increasing the release of nuclear and cellular
autoantigens, DAMPs (ATP and HGMB1) and inflammatory
cytokines (IL-1b and IL-18). A schematic rendition of the hy-
pothetical contribution of P2X7R, NLRP3 and associated mol-
ecules is shown in [Fig. 1].
Lupus is a polygenic disorder with a strong hereditary
component. Clinical data show a remarkable sex and ethnic
variability in disease severity, prevalence and incidence. A
large number of susceptibility genes have been identified in
spontaneous lupus mouse models [182,183]. They include the
lprmutation in the Fas receptor, that in MRL/lprmice causes a
lymphoproliferative syndrome. The P2X7R has been suggested
as a candidate susceptibility gene [184]. The P2X7R locus, i.e.
12q24, has been identified as SLE susceptibility locus (SLEB4) in
Hispanic and European American families [185] [186]. P2X7R
polymorphisms have been recently reported to associate with
susceptibility to SLE and lupus nephritis in a Chinese popu-
lation [187], whereas previous investigations had not detected
significant differences in the distribution of the 1513 AC
polymorphism in SLE patients respect to controls in Cauca-
sian populations [188,189]. Nevertheless, in SLE patients the
1513 AC SNP was associated with low P2X7R expression,
reduced induction of apoptosis of peripheral mononuclear
cells and decreased IL-1b release following stimulation by
ATP, suggesting an impaired elimination of self-reactive im-
mune cells [189].
Nowadays, only few drugs are available for SLE treatment,
some of them biologics [190]. Belimumab, a mAb targeting B
lymphocyte stimulating (BLyS) protein, thus preventing its
binding to B cell activating factor (BAFF) receptor, is the
biologic most widely used. Type I IFNs, are another potential
therapeutic target and Sifalimumab, a mAb that binds IFN-a
Fig. 1 e Suggested central role of P2X7R and NLRP3 inflammasome in the pathways leading to autoimmunity and tissue damage
in SLE. The different types of cell death can generate molecules that contribute to inflammation and tissue damage in SLE.
NETosis, which is dependent on NLRP3 inflammasome activation, produces NETs and the cathelicidin LL-37. Pyroptosis, also
dependent on NLRP3 inflammasome activation, causes HMGB1 and DNA release. Finally, defective apoptosis is responsible for
nucleic acid release. NETs/LL-37 activate the P2X7R leading to production and release of IL-1b and IL-18, thus promoting
inflammation. IL-1b is in turn responsible of increased NETs formation from neutrophils and LDGs. Interleukin-18 works in
combination with IL-6 and IL-23 to reduce T-reg and MDSC activity, to enhance Th17 activity and inflammation. NETs are also
responsible for EC damage with consequent release of immune stimulatory molecules and tolerance breaking. HMGB1
interaction with TLR4 contributes to inflammation through activation of NF-kB and release of the inflammatory cytokines TNF-
a and IL-6. TNF-a is responsible for keratinocyte apoptosis, a process that generates autoantigens. The alarmin HMGB1, is
released upon P2X7R/NLRP3 activation and in cooperation with DNA contributes to ANA formation. Nucleic acids are
responsible for production of ANAs that participate in formation of ICs. ICs on one hand, interact with RAGEs on endothelial
cells, thus causing vasculopathy, whereas on the other stimulate pDCs to produce IFN-a. Abbreviations: NETs: neutrophil
extracellular trap-associated proteins; HMGB1: high molecular group box-1; ANA: anti-nuclear antibodies; MDSC: myeloid
derived suppressor cells; pDCs: plasmacytoid dendritic cells; K: keratinocytes; LDGs: low-density granulocytes; TLR4: Toll-like
receptor 4; ICs: immune complexes; RAGEs: receptor for advanced glycation end products; NLRP3: NOD-like receptor family
pyrin domain-containing 3.
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 3 2 6e3 3 8332thus preventing IFN-a signalling, is currently in Phase I
clinical trial. Targeting inflammasome components and
related molecules is another promising strategy for the
treatment of SLE [191]. In this perspective, P2X7R antago-
nists, currently in clinical trials for the treatment of inflam-
matory diseases [130], might also find applications for the
treatment of SLE.Conclusion
The P2X7R is amain player in immunity and inflammation. Its
key role in IL-1b processing and release is an established fact,
but accruing evidence support its participation in many
additional immune responses such as T lymphocyte differ-
entiation, Ag presentation and granuloma formation.Transition of P2X7R knowledge from the laboratory to the
clinics has not been fast so far, despite efforts by Pharma In-
dustry to develop potent and selective P2X7R drug-like an-
tagonists. We think that this gap is in part due to less than
optimal selection of candidate human diseases for clinical
studies. In this review we offered an appraisal of literature
evidence supporting a possible contribution of P2X7R to the
pathogenesis of systemic lupus erythematosus, one of the
most relevant pathologies characterized by immune-
mediated tissue damage and inflammation. The challenge is
now to take all this knowledge to the patient's bed.Conflicts of interest
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